Share
2,126 Posts.
lightbulb Created with Sketch. 1777
clock Created with Sketch. 14/08/20
15:44
Share
Originally posted by sisyphean:
↑
I have been lurking on these boards for a while, but I have to jump in to agree with you. It's important to remember that SR-aGVHD represents a relatively modest prospective market (even when assuming an extension to adult SR-aGVHD). But what seems to be being overlooked by many is SI and Co's confidence in the (still only theorised) underlying mechanism of action of Remestemcel-L, which they clearly expect to prove itself in applications beyond SR-aGVHD (hence why they dipped their toes in the C-19 waters with the Mt Sinai trial). If SI and Co are right that Remestemcel-L MOA has the ability to treat a wide range of systemic inflammation-related diseases generally (incl. ARDS), then we are talking multiple label extensions with discrete markets that would dwarf the demand arising out of SR-aGVHD. But, with the exception of C-19-related ARDS, those extensions are long term propositions.
Expand
Hi @sisyphean ! I take it you probably were sound asleep in bed last night as the war of the words raged on between the MSB crack squad and the FDA missive? is actually happening. Its evidenced by the cell-surface markers. That's what makes out cells SO potent. The expression of TNFR1 (that then causes the NF-kappa beta signalling and the downstream secretion of the the immunomodulatory cytokines) and the inhibition of IL-2R alpha are the twin silver bullets in the mode of action that is key to calming the cytokine storm!https://www.fda.gov/media/141132/download
(20min delay)